Your session is about to expire
← Back to Search
Study Summary
This trial will compare the effectiveness of two different drugs for people with liver cancer that cannot be removed by surgery. The trial will also look at the safety and how well the drugs are tolerated in Japanese participants.
- Liver Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 512 Patients • NCT03430843Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- The tumor has spread and is blocking the main blood vessels in the liver or abdomen.You currently have a weakened immune system or an autoimmune disease, or you have had one in the past that could come back.You have advanced liver cancer that cannot be treated with local therapies and cannot be cured.You have a history of lung disease or inflammation, except if it was caused by radiation therapy.
- Group 1: Arm B: Sorafenib
- Group 2: Arm A: Tislelizumab & Safety Run-In Substudy [Japan Only]
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many sites are involved in the implementation of this trial?
"This clinical trial is presently enlisting participants from 19 sites, distributed amongst Orange, Lake Success and Nashville as well as other cities. To lessen your commuting costs if you decide to join the experiment, it is essential to pick the closest site available."
Are there any analogous experiments involving Tislelizumab?
"Initially tested in 2005 at Central Illinois Hematology Oncology Center, tislelizumab has seen 407 trials to date. Of the 165 active studies today, many are hosted out of Orange, California."
Is there currently an opportunity to join this research experiment?
"The clinicaltrials.gov database states that this trial, which was initially posted on December 28th 2017 and last updated on December 7th 2022, is no longer actively recruiting patients. However, there are still 2782 other studies currently searching for volunteers to participate in the research."
What types of illnesses can Tislelizumab be utilized to combat?
"Tislelizumab is used to combat the proliferation of radioactive iodine-refractory differentiated thyroid carcinoma (dtc) as well as gastrointestinal stromal tumors, hemangiosarcoma and leiomyosarcoma."
What is the current enrollment rate for this trial?
"At this time, enrollment for the trial has been suspended. According to records on clinicaltrials.gov, it was first made available in December 2017 and last modified in December 2022. If you are seeking alternate studies, there are currently 2617 trials involving carcinoma hepatocellular actively recruiting participants as well as 165 research initiatives concerning tislelizumab that have open admissions."
What potential risks have been associated with Tislelizumab use?
"Our team at Power has assigned a score of 3 to tislelizumab, indicating that there is both existing data confirming its efficacy and extensive safety research."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger